Daré Bioscience (Nasdaq:DARE) - Aandelenkoers, Nieuws & Analyse

DARE Overzicht aandelen

Daré Bioscience, Inc., een biofarmaceutisch bedrijf, identificeert, ontwikkelt en verkoopt producten voor de gezondheid van vrouwen in de Verenigde Staten.

Over het bedrijf

DARE fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Earnings are forecast to grow 61.01% per year

Risicoanalyse

Does not have meaningful revenue ($3M)

Does not have a meaningful market cap ($36M)

Shareholders have been diluted in the past year

Daré Bioscience, Inc. Concurrenten

MariMed

OTCPK:MRMD

US$61.5m

Nutriband

NasdaqCM:NTRB

US$65.8m

DURECT

NasdaqCM:DRRX

US$41.6m

Jushi Holdings

OTCPK:JUSH.F

US$86.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Daré Bioscience
Historische aandelenkoersen
Huidige aandelenkoers	US$4.16
52 Week Hoogtepunt	US$7.56
52 Week Laag	US$3.05
Bèta	1.39
11 maand verandering	28.82%
3 maanden verandering	29.19%
1 Jaar Verandering	-2.24%
33 jaar verandering	-79.37%
5 jaar verandering	-61.39%
Verandering sinds IPO	-94.22%

Recent nieuws en updates

Recent updates

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Oct 17

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Oct 10

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Aug 29

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Jun 30

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Apr 02

Diving Back Into Daré Bioscience Again

Jan 07

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Nov 26

Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study

Apr 26

Diving Into Daré Bioscience

Jan 31

Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dec 22

Dare Bioscience EPS misses by $0.06

Nov 12

Rendement voor aandeelhouders

	DARE	US Pharmaceuticals	US Markt
7D	6.4%	-3.7%	-1.6%
1Y	-2.2%	17.2%	30.8%

Rendement versus industrie: DARE underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.

Rendement versus markt: DARE underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is DARE's price volatile compared to industry and market?
DARE volatility
DARE Average Weekly Movement	9.4%
Pharmaceuticals Industry Average Movement	9.3%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: DARE has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: DARE's weekly volatility has decreased from 15% to 9% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	25	Sabrina Johnson	darebioscience.com

Daré Bioscience, Inc., een biofarmaceutisch bedrijf, identificeert, ontwikkelt en verkoopt producten voor de gezondheid van vrouwen in de Verenigde Staten. Het ontwikkelt therapieën op het gebied van anticonceptie, reproductieve gezondheid, menopauze, vruchtbaarheid en seksuele en vaginale gezondheid. Het bedrijf biedt XACIATO aan voor de behandeling van bacteriële vaginose bij vrouwelijke patiënten van 12 jaar en ouder.

Daré Bioscience, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Daré Bioscience zich tot de beurswaarde?
DARE fundamentele statistieken
Marktkapitalisatie	US$35.55m
Inkomsten(TTM)	-US$7.20m
Inkomsten(TTM)	US$2.84m

12.5x

P/S-verhouding

-4.9x

Koers/Winstverhouding

Is DARE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DARE resultatenrekening (TTM)
Inkomsten	US$2.84m
Kosten van inkomsten	US$21.65m
Brutowinst	-US$18.81m
Overige uitgaven	-US$11.60m
Inkomsten	-US$7.20m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.84
Brutomarge	-662.27%
Nettowinstmarge	-253.60%
Schuld/Eigen Vermogen Verhouding	161.3%

Hoe presteerde DARE op de lange termijn?

Bekijk historische prestaties en vergelijking

DARE Overzicht aandelen

Beloningen

Risicoanalyse

Daré Bioscience, Inc. Concurrenten

OTCPK:MRMD

US$61.5m

NasdaqCM:NTRB

US$65.8m

NasdaqCM:DRRX

US$41.6m

OTCPK:JUSH.F

US$86.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Daré Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $18.08963 million.

Daré Bioscience, Inc., Annual General Meeting, Jun 05, 2024

Recent updates

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Daré Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $18.08963 million.

Daré Bioscience, Inc., Annual General Meeting, Jun 05, 2024

Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer

Daré Bioscience, Inc. Announces Executive Changes

Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel

Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel

Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study

Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1

Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

New major risk - Revenue and earnings growth

We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate

Daré Bioscience, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Price target decreased by 11% to US$5.33

New major risk - Financial position

New major risk - Revenue size

Daré Bioscience, Inc. Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Daré Bioscience Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Dare Bioscience, Inc. Announces Additional Positive Data from Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women

New minor risk - Profitability

Consensus revenue estimates decrease by 18%

Daré Bioscience, Inc. Provides Update on Activities to Support Commercial Launch of XACIATO

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Dare Bioscience, Inc. Announces Positive Topline Data from the Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Consensus revenue estimates increase by 29%, EPS downgraded

No longer forecast to breakeven

Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?

Price target increased by 13% to US$6.00

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

Daré Bioscience, Inc. Announces Positive Pharmacokinetic Results from the DARE-HRT1 Phase 1 / 2 Study

Forecast to breakeven in 2025

Daré Bioscience Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates fall by 38%

Consensus forecasts updated

Price target decreased to US$5.33

Daré Bioscience, Inc. Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

Daré Bioscience Announces Subject Screening for Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

Daré Announces Topline Results of Its Phase 1/2 Clinical Study of Dare-HRT1

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Daré Bioscience, Inc. Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Daré Bioscience Announces Interim Analysis of Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Consensus revenue estimates increase by 24%

No longer forecast to breakeven

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Daré Bioscience, Inc., Annual General Meeting, Jul 14, 2022

Consensus revenue estimates increase by 11%

Daré Bioscience, Inc., Annual General Meeting, Jun 23, 2022

Price target increased to US$8.25

Forecast to breakeven in 2024

Daré Bioscience, Inc. Initiates Phase 1/2 Clinical Study of DARE-HRT1

Consensus revenue estimates increase by 43%